

Telefax Transmittal
Cover sheet**FAX RECEIVED**

MAY 22 2003

GROUP 1600

OFFICIALIntervet Inc.
405 State Street
P.O. Box 318
Millsboro, DE 19966
(302) 934-8051

May 21, 2003

5...pages including cover sheet.

PERSON TO:	COMPANY/DEPT TO:	FAX NUMBER:
------------	------------------	-------------

Examiner V. Portner

Group Art Unit 1645

703 308 4242

PERSON FROM:	COMPANY/DEPT FROM:	FAX NUMBER:
--------------	--------------------	-------------

William P. Ramey III

Intervet, Millsboro

302 934 4305

Patent Department

RE: USSN 09/544,683

Attorney Docket Number I 99471 US

Jacobs et al

Please accept the documents that follow in the above-identified application:

Supplemental Response to Office Action of February 6, 2003 (4 pages)

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED, AND MAY CONTAIN PROPRIETARY INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF YOU ARE NOT THE ADDRESSEE, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, NOTIFY US IMMEDIATELY BY TELEPHONE (COLLECT). THANK YOU.

Certificate of Facsimile Transmission

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below:

By: Karen L S
Date: 5/21/03

AM DT
27/2 (NE)
Ondra
6/4/03

Atty Docket No.: I/99471 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

JACOBS ET AL.

Serial No.: 09/544,683

Group Art Unit: 1645

Filed: April 7, 2000

Examiner: Portner, V.

For: CAMPYLOBACTER VACCINE

(REDACTED)
(REDACTED)

SUPPLEMENTAL RESPONSE TO OFFICE ACTION OF FEBRUARY 6, 2003

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir,

I. Introduction

Applicants respectfully supplementally respond to the Office Action of February 6, 2003 as follows, please charge any required fees to Deposit Account 02-2334 and credit any credits. Applicants' response is limited to a correct set of amended claims pursuant to 37 CFR §1.121, no estoppel should result from said amendment.